Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

13.3%

2 terminated/withdrawn out of 15 trials

Success Rate

77.8%

-8.7% vs industry average

Late-Stage Pipeline

13%

2 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

7(46.7%)

Phase 1

6(40.0%)

Phase 3

2(13.3%)

15Total

Phase 2(7)

Phase 1(6)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT03149211Phase 3Withdrawn

To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults

Role: lead

NCT04406727Phase 3Not Yet Recruiting

UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection

Role: lead

NCT04620304Phase 1Completed

Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients

Role: lead

NCT03164447Phase 2Unknown

UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients

Role: lead

NCT05056974Phase 2Completed

A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs

Role: lead

NCT05298215Phase 2Unknown

A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria

Role: lead

NCT04175704Phase 1Unknown

Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria

Role: lead

NCT03595995Phase 2Unknown

A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621

Role: lead

NCT03743376Phase 2Completed

The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients

Role: lead

NCT04620291Phase 1Unknown

Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults

Role: lead

NCT03632291Phase 1Completed

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients

Role: lead

NCT04041362Phase 2Withdrawn

the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients

Role: lead

NCT02346760Phase 1Completed

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UB-621 in Healthy Volunteers

Role: lead

NCT03013881Phase 1Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy Volunteers

Role: lead

NCT02369146Phase 2Completed

To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults

Role: lead

All 15 trials loaded